GlassScriptPhysician profile
Caroline Wilson
NPI 1447792338
$7,298.48
in general payments reported to CMS, 2019-2025
32 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,528 · 2022: $1,230 · 2023: $1,396 · 2024: $1,960 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,397 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,397.02 |
| Education | $142.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,042.18 | 2021-2025 | |
| Abbvie INC. | $990.88 | 2021-2025 | |
| Incyte Corporation | $855.04 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $604.83 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $460.62 | 2021-2025 | Absorica Ld, Winlevi, Odomzo |
| Dermavant Sciences, INC. | $377.70 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $372.55 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Janssen Biotech, INC. | $230.98 | 2021-2024 | Tremfya |
| Organon LLC | $216.99 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $178.17 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $175.86 | 2021-2025 | Adbry, Anzupgo |
| Vyne Pharmaceuticals INC. | $172.54 | 2021 | |
| Galderma Laboratories, L.P. | $166.30 | 2021-2025 | Aklief, Epsolay, Nemluvio |
| Mayne Pharma Commercial LLC | $166.07 | 2021-2025 | |
| Journey Medical Corporation | $132.80 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $132.06 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $124.42 | 2022-2025 | Taltz, Ebglyss |
| Pfizer INC. | $121.17 | 2021-2023 | |
| Ucb, INC. | $117.23 | 2023-2025 | Cimzia, Bimzelx |
| Janssen Pharmaceuticals, INC | $116.87 | 2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $112.37 | 2021-2024 | Dupixent |
| Genzyme Corporation | $103.70 | 2021-2022 | |
| Allergan, INC. | $68.59 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.24 | 2023-2025 | Spevigo |
| Nabriva Therapeutics, Plc | $50.25 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $37.89 | 2022 | |
| Epi Health, LLC | $27.74 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $23.36 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.82 | 2023 | Ycanth |
| Botanix Sb INC | $17.22 | 2025 | Sofdra |
| Takeda Pharmaceuticals U.S.A., INC. | $14.64 | 2025 | Entyvio |
| Strata Skin Sciences, INC. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.